Cargando…

Intelligent Telehealth in Pharmacovigilance: A Future Perspective

Pharmacovigilance improves patient safety by detecting and preventing adverse drug events. However, challenges exist that limit adverse drug event detection, resulting in many adverse drug events being underreported or inaccurately reported. One challenge includes having access to large data sets fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Edrees, Heba, Song, Wenyu, Syrowatka, Ania, Simona, Aurélien, Amato, Mary G., Bates, David W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9112241/
https://www.ncbi.nlm.nih.gov/pubmed/35579810
http://dx.doi.org/10.1007/s40264-022-01172-5
_version_ 1784709378966814720
author Edrees, Heba
Song, Wenyu
Syrowatka, Ania
Simona, Aurélien
Amato, Mary G.
Bates, David W.
author_facet Edrees, Heba
Song, Wenyu
Syrowatka, Ania
Simona, Aurélien
Amato, Mary G.
Bates, David W.
author_sort Edrees, Heba
collection PubMed
description Pharmacovigilance improves patient safety by detecting and preventing adverse drug events. However, challenges exist that limit adverse drug event detection, resulting in many adverse drug events being underreported or inaccurately reported. One challenge includes having access to large data sets from various sources including electronic health records and wearable medical devices. Artificial intelligence, including machine learning methods, such as natural language processing and deep learning, can detect and extract information about adverse drug events, thus automating the pharmacovigilance process and improving the surveillance of known and documented adverse drug events. In addition, with the increased demand for telehealth services, for managing both acute and chronic diseases, artificial intelligence methods can play a role in detecting and preventing adverse drug events. In this review, we discuss two use cases of how artificial intelligence methods may be useful to improve the quality of pharmacovigilance and the role of artificial intelligence in telehealth practices.
format Online
Article
Text
id pubmed-9112241
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-91122412022-05-17 Intelligent Telehealth in Pharmacovigilance: A Future Perspective Edrees, Heba Song, Wenyu Syrowatka, Ania Simona, Aurélien Amato, Mary G. Bates, David W. Drug Saf Leading Article Pharmacovigilance improves patient safety by detecting and preventing adverse drug events. However, challenges exist that limit adverse drug event detection, resulting in many adverse drug events being underreported or inaccurately reported. One challenge includes having access to large data sets from various sources including electronic health records and wearable medical devices. Artificial intelligence, including machine learning methods, such as natural language processing and deep learning, can detect and extract information about adverse drug events, thus automating the pharmacovigilance process and improving the surveillance of known and documented adverse drug events. In addition, with the increased demand for telehealth services, for managing both acute and chronic diseases, artificial intelligence methods can play a role in detecting and preventing adverse drug events. In this review, we discuss two use cases of how artificial intelligence methods may be useful to improve the quality of pharmacovigilance and the role of artificial intelligence in telehealth practices. Springer International Publishing 2022-05-17 2022 /pmc/articles/PMC9112241/ /pubmed/35579810 http://dx.doi.org/10.1007/s40264-022-01172-5 Text en © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Leading Article
Edrees, Heba
Song, Wenyu
Syrowatka, Ania
Simona, Aurélien
Amato, Mary G.
Bates, David W.
Intelligent Telehealth in Pharmacovigilance: A Future Perspective
title Intelligent Telehealth in Pharmacovigilance: A Future Perspective
title_full Intelligent Telehealth in Pharmacovigilance: A Future Perspective
title_fullStr Intelligent Telehealth in Pharmacovigilance: A Future Perspective
title_full_unstemmed Intelligent Telehealth in Pharmacovigilance: A Future Perspective
title_short Intelligent Telehealth in Pharmacovigilance: A Future Perspective
title_sort intelligent telehealth in pharmacovigilance: a future perspective
topic Leading Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9112241/
https://www.ncbi.nlm.nih.gov/pubmed/35579810
http://dx.doi.org/10.1007/s40264-022-01172-5
work_keys_str_mv AT edreesheba intelligenttelehealthinpharmacovigilanceafutureperspective
AT songwenyu intelligenttelehealthinpharmacovigilanceafutureperspective
AT syrowatkaania intelligenttelehealthinpharmacovigilanceafutureperspective
AT simonaaurelien intelligenttelehealthinpharmacovigilanceafutureperspective
AT amatomaryg intelligenttelehealthinpharmacovigilanceafutureperspective
AT batesdavidw intelligenttelehealthinpharmacovigilanceafutureperspective